A transformative approach
Fully integrated with end-to-end capabilities
Legend Biotech operates with a global network to efficiently and rapidly develop cell therapies from discovery through commercialization
Robust, global research and development infrastructure and pipeline
- We focus our research and development on the areas of greatest unmet need
- We have roughly 350 scientists and engineers dedicated to cell therapy R&D), with employees recruited from leading laboratories
- Our dedicated R&D teams based in China, Ireland, and the United States are working to develop potential best-in-class proprietary technology platforms
- By design, our CAR-T, TCR-T, and allogenic platforms are complementary and customizable
- Speed to market is enhanced by our global integrated R&D model and infrastructure
Rapidly advancing clinical assets
- Accelerating development and speed to market of our clinical compounds through global partnerships
- Partnering with leading clinicians in their respective fields to rapidly advance our pipeline and platforms
- Reducing clinical program risk by leveraging data through our global R&D network
- Attracting global talent with extensive experience in all stages of clinical development
- Maintaining focus on quality and compliance throughout clinical development
Established global manufacturing network
- Our network consists of three manufacturing facilities capable of producing clinical and commercial CAR-T supplies
- We are working with industry-leading technologies and service providers to innovate the CAR-T manufacturing process, optimize the end-to-end supply chain, and streamline the product delivery model
Manufacturing Sites
The safety and efficacy of the agents and/or uses under investigation have not been established. There is no guarantee that the agents will receive health authority approval or become commercially available in any country for the uses being investigated.
Expanding our commercial footprint
- We are building our commercial infrastructure and footprint for ciltacabtagene autoleucel (cilta-cel)* as part of our collaboration with Janssen Biotech, Inc.
- The established commercial capabilities and infrastructure will pave the way for our future pipeline products
- We have hired and continue to recruit top talent with extensive oncology experience launching and commercializing CAR-T and other blockbuster brands
- We strategically build the most efficient and effective go-to-market model to maximize the reach of cell therapy
The safety and efficacy of the agents and/or uses under investigation have not been established. There is no guarantee that the agents will receive health authority approval or become commercially available in any country for the uses being investigated.
*Cilta-cel is a B cell-directed chimeric antigen receptor T-cell (CAR-T) therapy being investigated for the treatment of multiple myeloma by regulatory authorities around the world.
